Phosphoinositide 3-kinase (PI3K) type IA is a heterodimer of a catalytic subunit, p110, and a regulatory subunit, p85. Here we show that p85 contains a GTPase-responsive domain and an inhibitory domain, which together form a molecular switch that regulates PI3K. H-Ras and Rac1 activate PI3K by targeting the GTPase-responsive domain. The stimulatory effect of these molecules, however, is blocked by the inhibitory domain, which functions by binding to tyrosine-phosphorylated molecules and is neutralized by tyrosine phosphorylation. The complementary effects of tyrosine kinases and small GTPases on the p85 molecular switch result in synergy between these two classes of molecules toward the activation of the PI3K/ Akt pathway.
Introduction
with direct binding between Ras and p110 (Rodriguez-Viciana et al., 1994) , while PI3K activation by Rac1 may be mediated by binding of Rac1 to p85 (Tolias et al., 1995; Zheng et al., Phosphoinositide 3-kinase (PI3K) type IA, a heterodimer of a regulatory subunit (p85) and a catalytic subunit (p110), catalyzes 1994). However, we and others have recently found that direct interaction of PI3K with either H-Ras or Rac1 is not required the phosphorylation of PtdIns-4,5-P 2 to form PtdIns-3,4,5-P 3 (Wymann and Pirola, 1998) . PtdIns-3,4,5-P 3 , in turn, regulates for PI3K activation (Karasarides et al., 2001 ; see Supplemental Figure S1 at http://www.cancercell.org/cgi/content/full/1/2/ a diverse array of cellular functions including apoptosis, proliferation, differentiation, and intermediary metabolism (Chan et al., 181/DC1). Moreover, constitutively active Ras activates the PI3K/Akt pathway in synergy with Src (Datta et al., 1996 ), sug-1999 Rameh and Cantley, 1999) . PI3K is activated rapidly following growth factor stimulation and crosslinking of cell adhegesting that signals transduced via small GTPases and tyrosine kinases regulate this pathway cooperatively. sion molecules (Rameh and Cantley, 1999) . Despite extensive studies on the mechanism of PI3K activation by these signals,
The studies in this manuscript reexamine the role of tyrosine kinases and small GTPases in PI3K activation in vivo. The reason however, significant questions remain unanswered.
Earlier studies suggested that the binding of the regulatory we focus on the regulation of PI3K in vivo is that critical factors involved in its regulation are lost upon purification. Thus, in the subunit of PI3K to tyrosine-phosphorylated molecules is directly responsible for PI3K activation (Backer et al., 1992 ; Carpenter absence of growth factor or integrin stimulation, PI3K fails to catalyze PtdIns-3,4,5-P 3 synthesis in vivo (Wymann and Pirola, et al., 1993) . However, recent in vitro studies (Layton et al., 1998) and earlier in vivo studies (Fukui and Hanafusa, 1989; . However, the enzyme becomes constitutively active upon purification. Moreover, Carpenter et al. found that higher PI3K-Varticovski et al., 1991) suggested that binding is not sufficient to activate PI3K. Other studies showed that PI3K is also actispecific activity in vitro correlates with increasing purity of PI3K preparations (Carpenter et al., 1990) . Finally, PI3K immunopurivated by small GTPase molecules such as Ras and Rac1 (Nishida et al., 1999; Rodriguez-Viciana et al., 1994) . These molefied from serum-starved cells has the same specific activity as PI3K from PDGF-stimulated cells . These studies cules activate PI3K by diverse, although not clearly defined, mechanisms. Thus, PI3K activation by Ras has been correlated indicate that inhibitory factors, lost upon purification, block PI3K activity in vivo (Carpenter et al., 1990) . Though phosphotyrosine peptides have been shown to modestly enhance type IA PI3K activity in vitro (Backer et al., 1992; Carpenter et al., 1993) , Layton et al. showed, and we confirmed, that this enhancement depends on conditions used for the in vitro assay (Layton et al., 1998 ; see Supplemental Figure S2 at http://www.cancercell. org/cgi/content/full/1/2/181/DC1) and that phosphotyrosine binding alone is not sufficient to activate PI3K in vivo. Based on the results of the studies described in this report, we propose a unifying model according to which all tyrosine kinases and small GTPases activate PI3K by acting synergistically on a molecular switch in p85.
Results

Wild-type p85 and carboxy-terminally truncated p85 exert opposite effects on PtdIns-3,4,5-P 3 synthesis induced by H-Ras or Rac1
Earlier studies had shown that a truncated p85 molecule lacking the carboxy-terminal SH2 domain and 52 adjacent amino acids from the inter-SH2 (iSH2) region, referred to as p85⌬onc in this communication, activates PI3K constitutively and transforms cells in culture (Jimenez et al., 1998) . Wild-type p85, on the other hand, blocks H-Ras-induced PI3K activation and cellular transformation . This raised the question whether p85⌬onc and p85 differ in their ability to regulate PI3K activation by H-Ras. To address this question, we used a thin-layer chromatography-based assay (Maehama and Dixon, 1998) to separate PtdIns-3,4,5-P 3 from lipid extracts of 32 P-labeled NIH3T3 cells transfected with Hemagglutinin (HA)-tagged constructs of wild-type p85 (HA-p85-WT) or p85⌬onc (HA-p85⌬onc) and constitutively-active H-Ras (H-Ras G12V) in the combinations shown in Figure 1B . HA-p85-WT and HA- tagged p85-WT and p85⌬onc constructs. B: Top: p85-WT inhibits while p85⌬onc enhances H-Ras-induced PtdIns-3,4,5-P 3 production. The indiand p85⌬onc, however, had diametrically opposite effects when cated constructs were transiently transfected into NIH3T3 cells. Sixteen hours cotransfected with Ras in that whereas p85 inhibited the activaafter transfection, the cells were cultured in serum-free media. Five hours tion of PI3K, p85⌬onc enhanced it dramatically. Figure 1C later, they were labeled with 32 P-orthophosphate for 1.5 hr. Total phospholipshows that the synergy between H-Ras and p85⌬onc is wortids were analyzed by thin-layer chromatography. Bottom: p85-WT inhibits mannin sensitive, and therefore, PI3K dependent.
while p85⌬onc enhances H-Ras-induced Akt phosphorylation. Immunoblots of cell extracts from duplicate transfections were probed with an antibody PtdIns-3,4,5-P 3 synthesized by the activated PI3K is rethat recognizes Akt phosphorylated at Thr308 or with antibodies that recogquired for activation of the Akt kinase Figure S3 at http://www.cancercell.org/cgi/content/full/1/2/181/DC1). that the levels of PtdIns-3,4,5-P 3 correlate with the phosphorylaWe next examined whether p85⌬onc synergizes with small tion of Akt at Thr308. Based on these observations, we decided GTPases other than Ras to activate the PI3K pathway. Figure  to use the in vitro kinase activity of Akt to monitor the in vivo 1D (upper gel) shows that the combination of transiently transactivity of PI3K. The results of critical experiments were confected, constitutively active Rac1 (Rac1 Q61L) and p85⌬onc in firmed by direct measurement of the intracellular levels of NIH3T3 cells dramatically enhanced the intracellular levels of PtdIns-3,4,5-P 3 . PI3K activation via the synergistic actions of Rac1 and PtdIns-3,4,5-P 3 . The lower gel of the same figure shows again p85⌬onc does not depend on the binding of Rac1 to p110, In vitro kinase assays of FLAG-Akt revealed that membranetargeted p85 is similar to the wild-type protein in that it does because these proteins do not interact (Tolias et al., 1995; Zheng et al., 1994) . Therefore, if Rac1 and H-Ras synergize with not activate the PI3K/Akt pathway by itself and in that it blocks activation of the pathway by H-Ras ( Figure 2B ). Myrp85⌬onc, p85⌬onc via similar mechanisms, the synergy of H-Ras with p85⌬onc should also be independent of the interaction between on the other hand, was similar to p85⌬onc in that it activated the PI3K/Akt pathway both alone and in synergy with H-Ras H-Ras and p110. Recent studies by us and others revealed that this is indeed the case. Karasarides et al. (2001) recently showed ( Figure 2C ). We conclude that association of p85 with the plasma membrane is not sufficient to activate PI3K. Therefore, the carthat an activated H-Ras mutant (Y64G/Y71G/F156L), which fails to bind p110, activates the PI3K/Akt pathway in vivo. Similarly, boxy-terminal truncation of p85 is unlikely to activate PI3K by targeting the enzyme to the plasma membrane. A more likely we found that both H-Ras G12V/E37G and H-Ras G12V/Y40C, two activated H-Ras mutants of which only the latter interacts possibility is that truncation unveils a domain in p85 that responds to Ras-or Rac1-transduced signals to activate PI3K with p110 White et al., 1995) , synergize equally well with p85⌬onc to activate PI3K (see Sup-(GTPase-responsive domain, GRD) . Subsequent experiments were designed to map the GRD within p85. plemental Figure S1 at http://www.cancercell.org/cgi/content/ full/1/2/181/DC1). The same figure shows that overexpression of the BCR domain of p85, which is known to bind Rac1 (Tolias A protein motif within the iSH2 domain of p85 synergizes with H-Ras and Rac1 to activate Zheng et al., 1994) , does not inhibit PI3K activation by Rac1. Therefore, the Rac1/p85 interaction is also not required the PI3K/Akt pathway The p85 regulatory subunit of PI3K contains several protein for PI3K activation.
domains, including SH3, BCR homology, two SH2 domains, and an inter-SH2 domain (iSH2; Figure 3A ). Computer modeling Membrane localization of p85 is not sufficient to activate PI3K of the iSH2 domain suggested that this region resembles a coiled-coil structure (Wymann and Pirola, 1998) . A motif (TIF), Truncated p85 is thought to activate PI3K by directing it to the plasma membrane (Jimenez et al., 1998) . We, therefore, tested previously mapped within this structure, binds the PI3K catalytic subunit, p110 . The TIF motif is highly conwhether membrane-associated full-length p85 is functionally similar to the carboxy-terminally truncated protein. To this end, served across p85 subtypes (␣, ␤, and ␥) and across species (bovine, rat, and Drosophila; Figure 3A ). Other conserved motifs p85 fused at its amino terminus to a peptide encoding the Src myristoylation signal (Myrp85-WT; Figure 2A ) was transiently include a motif we named IKR, which is rich in isoleucine, lysine, and arginine residues, and a motif we named LED, which is rich expressed in NIH3T3 cells in combination with FLAG-Akt or FLAG-Akt plus H-Ras. Myrp85⌬onc was used as a control. The in leucine, glutamic acid, and aspartic acid residues. The LED motif is located downstream from the IKR motif and corresponds cells were lysed 48 hr later, following overnight serum starvation. Akt activation in this and subsequent experiments was deterto the carboxyl terminus of the iSH2 domain. The carboxyl terminus of the IKR motif corresponds to the breakpoint of the mined by measuring the phosphorylation of histone 2B (H2B) by immunoprecipitated Akt.
p85 oncogenic truncation. Given that the p85 oncogenic truncation separates the TIF phorylated Thr308 motif of Akt revealed that the deletion of IKR abolishes iSH2⌬onc function ( Figure 3C ). We conclude that the and IKR motifs from the LED motif, we examined whether the IKR motif is a required component of the GRD domain. TIF/IKR portion of iSH2 (p85-iSH2⌬onc; Figure 3A ) synergizes with Ras or Rac1 to activate the PI3K pathway. To this end, we transfected NIH3T3 cells with FLAG-Akt and activated H-Ras
The LED and cSH2 motifs of p85 define a modular inhibitory domain G12V or activated Rac1 Q61L in combination with p85-iSH2⌬onc. The Akt kinase activity was measured 48 hr later, following
The blockage of Ras signal by wild-type p85, but not by p85⌬onc, suggests that the carboxy-terminal region of this molserum starvation for 16 hr. The results showed that iSH2⌬onc, indeed, activates the PI3K/Akt pathway, alone and in synergy ecule may contain an inhibitory domain. To test this hypothesis, we transfected NIH3T3 cells with H-Ras G12V in combination with H-Ras or Rac1 ( Figure 3B ). However, iSH2⌬onc did not bind either Ras or Rac1 (data not shown), suggesting that the with expression constructs of the carboxyl terminus of p85 (p85-CT, amino acids 514-725) or p85-DN, a known dominant-negafunctional interaction between iSH2⌬onc and these molecules is likely to be indirect. Next, we examined whether the IKR motif tive mutant of p85 (deletion of amino acids 479-513) . After overnight serum starvation, the activity of is necessary for iSH2⌬onc function. To this end, the intact nSH2/ iSH2⌬onc and nSH2/ iSH2⌬onc molecules with carboxy-termicotransfected FLAG-Akt was examined. The results showed that p85-CT is as efficient as p85-DN at inhibiting the Ras signal nal deletions of the IKR or the IKR plus TIF motifs were fused to Hemagglutinin-tagged green fluorescence protein (HA-GFP).
( Figure 4B ) and confirmed that the carboxyl terminus of p85 contains a modular inhibitory domain. The GFP fusion constructs were transiently transfected in combination with FLAG-Akt into NIH3T3 cells. Probing an immuTo map the p85-CT motifs required for the inhibitory function, we fused p85-CT or portions of it with HA-GFP (Figure noblot of cell lysates with an antibody that recognizes the phos- To distinguish between these possibilities, we examined by H-Ras-G12V. The indicated constructs, in combination with a FLAG-cAkt whether p85-CT inhibits the activity of p110-CAAX, a membrane construct, were transiently transfected into NIH3T3 cells. The Akt kinase activity was measured in anti-FLAG immunoprecipitates. Expression of FLAG-Akt bound, constitutively active p110 mutant (Klippel et al., 1996) . from the transfected cells 48 hr later showed that the p85 inhibi- ing the effects of p85-CT on membrane-targeted p110␣ and was measured by immunoblotting. Expression of the transfected constructs p110␥, two type I PI3K molecules of which only the former binds was determined by probing immunoblots with the corresponding antip85, showed that p85-CT inhibits only p110␣ ( Figure 5B ).
bodies.
PtdIns-3,4,5-P 3 levels may be induced because of PI3K activation. Alternatively, they may be induced because of inactivation of PTEN, a tumor-suppressor gene that encodes a PtdIns-3,4,5-P 3 phosphatase (Cantley and Neel, 1999) . The difference 4A). Expression of the GFP fusion constructs in combination between p110␣ and p110␥ suggests that the p85 inhibitory with H-Ras-G12V in NIH3T3 cells showed that the IKR motif is domain targets PI3K and not PTEN. To address this hypothesis, not required for the p85 inhibitory function ( Figure 4C ). Addip85-CT or p85-DN constructs were transfected into the PTEN tional deletions showed that the minimal inhibitory domain connull cell line, U87MG (Li et al., 1997) , in combination with constitains both the LED and the carboxy-terminal SH2 domains.
tutively active H-Ras G12V and FLAG-Akt. The results showed Deletion of either domain abolished inhibitory function (Figure that p85-CT blocks activation of the PI3K/Akt pathway by Ras, 4D). Both the inhibitory protein LED/cSH2 and the noninhibiting even in the absence of PTEN ( Figure 5C ). We conclude that the cSH2 were able to bind phosphotyrosine targets, suggesting that they folded properly (data not shown).
p85 inhibitory domain targets PI3K and not PTEN. Figure 6B . In vitro kinase assays of Akt carried out 48 hr later, after overnight serum starvation, confirmed that p85-WT blocks Akt activation by H-Ras but not by Src. One possible explanation for the failure of p85 to block PI3K activation by Src is that Src may neutralize the p85 inhibitory domain. Therefore, when coexpressed with constitutively active Src, wild-type p85 may become functionally equivalent to p85⌬onc. This model, if correct, would explain our previous finding that Src and H-Ras synergize to activate the PI3K/Akt pathway (Datta et al., 1996) . To test this hypothesis, we wanted to examine whether constitutively active Ras enhances Src plus p85-induced PI3K/Akt activation in NIH3T3 cells. However, such an experiment would be difficult to interpret, because Src is known to activate Ras (Marais et al., 1995) . To carry out this experiment, therefore, we wanted to use a Src mutant that retained the ability to neutralize the p85 inhibitory domain, but no longer activated Ras. A G2A mutation that inactivates the Src myristoylation signal ( Figure 6A ) renders Src defective in Ras activation (Marais et al., 1995) without affecting its tyrosine kinase activity (Kamps et al., 1986) . Consistent with these data, a Src G2A mutant (NM-Src) retained full tyrosine kinase activity Figure 6C ). In addition, this mutant did not activate the used in this report. B: p85-WT inhibits Akt activation by Ras but not by Src. Figure 6C ). This mutant, similar to wild-type NIH3T3 cells were transfected with the indicated constructs. Akt activity was Src, was able to phosphorylate both endogenous and exoge- Figure 6E ). Both measurements confirmed that p85-WT cell lysates with the corresponding antibodies. E: The nonmyristoylated Src does not inhibit PI3K activation by Ras signals in the presence abolishes the inhibition of PtdIns-3,4,5-P 3 production by p85. Constitutively of NM-Src. We conclude that Src transmits tyrosine-phosphoryactive H-Ras-G12V was transfected in combination with p85-WT or nonmyrislation signals that neutralize the inhibitory domain of p85.
PI3K/Akt pathway (
toylated Src Y527F into NIH3T3 cells. Sixteen hours after transfection, 32 Plabeled PtdIns-3,4,5-P 3 was measured as in Figure 1 (top gel). Akt phosphoryMany cytoplasmic tyrosine kinases and receptor tyrosine lation at Thr308 was measured by immunoblotting in cell lysates from duplikinases are known to activate the PI3K/Akt pathway. We, therecate transfections. Expression of transfected constructs was determined by fore, tested some of these tyrosine kinases for their ability to probing immunoblots with the corresponding antibodies.
neutralize the p85 inhibitory domain. Using synergy with Ras as the assay, we found that the Src catalytic domain (without its SH2/SH3 domains), other cytoplasmic tyrosine kinases (Syk and Abl but not p125 FAK ), and receptor tyrosine kinases (EGF, also showed that in addition to Ras and Rac1, small GTPases PDGF, and IGF-1 receptors) all neutralize the inhibitory function R-Ras and CDC42, but not RhoA, cooperate with tyrosine kiof p85 (see Supplemental Figure S4 at http://www.cancercell.
nases to activate the PI3K/Akt pathway (see Supplemental Figure S5 ). org/cgi/content/full/1/2/181/DC1). Using the same assay, we the arginine residue of the FLVR motif (Kuriyan and Cowburn, 1997) . We, therefore, coexpressed the p85-CT R649L FLVR mutant, which no longer binds tyrosine-phosphorylated molecules (data not shown), in combination with Ras G12V into NIH3T3 cells, and we examined whether the mutant continues to inhibit PI3K/Akt activation by Ras. The result showed that the R649L mutation abolished the inhibition of p85-CT ( Figure  7B ). We conclude that phosphotyrosine binding is required for inhibition.
In addition to enabling phosphotyrosine binding, tyrosine kinases, such as Abl and Lck, directly phosphorylate p85 cSH2 at tyrosine residue 688 (von Willebrand et al., 1998) . To determine whether phosphorylation of this residue is involved in the neutralization of the p85 inhibitory domain, we mutated it to a phosphomimic aspartic acid (p85-CT Y688D). Coexpression of p85-CT Y688D and Ras G12V in NIH3T3 cells showed that this mutation abolished the inhibitory effect of p85-CT ( Figure 7B ). On the other hand, p85-CT with a tyrosine to phenylalanine mutation at this site (Y688F) continued to block Akt activation by Ras ( Figure 7C ). Both p85-CT mutants were able to bind tyrosine-phosphorylated molecules (data not shown), suggesting that they fold properly. Consistent with these data, a Y688D mutant of p85 continued to bind p110 but failed to inhibit the basal activity of Akt in Cos7 cells (Cuevas et al., 2001 ). We, therefore, conclude that both phosphotyrosine binding and Y688 phosphorylation regulate p85 inhibitory function.
Since Rodriguez-Viciana et al. showed that full-length p85 blocks cell transformation by Ras (Rodriguez-Viciana et al., 1997), we tested whether the inhibitory domain alone also blocks transformation. To this end, we transfected p85-CT together with activated Ras into NIH3T3 cells. Scoring for foci of transformation two weeks later revealed that the p85 inhibitory domain is sufficient to block Ras-induced transformation ( Figure 7D ). This blockage is specific because both the p85-CT (R649L) and p85-cSH2 constructs failed to block. Blockage of transforma- tion, the cells were fixed with 70% methanol, and they were stained with Giemsa (Chan et al., 1994) .
we took advantage of observations showing that in serumstarved adherent cells, tyrosine kinase and small GTPase signals are induced by matrix adhesion and that the small GTPase signals are required for PI3K/Akt activation ; cSH2 mutations abolish p85 inhibitory function King et al., 1997) . We, therefore, transfected mouse 3Y1 fibroThe preceding data suggest that Src and other tyrosine kinases blasts with wild-type FLAG-Akt alone or in combination with transmit signals that neutralize the p85 inhibitory domain. Since kinase-inactive Src K279M. Following serum starvation, the the inhibitory domain encompasses the p85 carboxy-terminal cells were trypsinized and replated onto fibronectin-coated SH2 motif (cSH2; Figure 7A ), we asked whether its inhibitory plates or control polylysine-coated plates for 30 min. The results function depends on phosphotyrosine binding. Binding of all SH2 domains to phosphotyrosine can be abolished by mutating showed that Akt activation in the fibronectin-coated plates is inhibited by Src K279M ( Figure 8A ). These results support the hypothesis that Src signals are required, in combination with small GTPase signals, for PI3K/Akt activation by integrin stimulation.
To further explore the physiological role of complimentary signals transduced by tyrosine kinases and small GTPases, we employed suspension cultures of immortalized keratinocytes (HaCaT cells; Frisch and Francis, 1994) . Cell culture under conditions of forced suspension precludes integrin engagement and signaling and can be performed in defined media free of exogenous growth factors. In the absence of integrin-generated signals, these cells fail to activate the PI3K/Akt pathway and undergo apoptosis (anoikis). Previous studies, using suspension cultures of MDCK cells, suggested that activated Ras alone activates the PI3K/Akt pathway and rescues the cells from anoikis . These findings suggested that, in this experimental setting, Ras alone was sufficient to activate PI3K/ Akt and seemingly argued against an obligatory role of tyrosine kinases in this process. However, all these experiments were performed in serum-containing media which could generate tyrosine kinase signals that synergize with Ras. To avoid this problem, our experiments were carried out in serum-free defined media. The results ( Figure 8B) showed that constitutively active H-Ras G12V activates the PI3K/Akt pathway and rescues cells from anoikis only in suspension cultures supplemented with epidermal growth factor (EGF). Ras G12V-alone in the absence of EGF and EGF-alone in the absence of H-Ras G12V were inefficient in PI3K/Akt activation and failed to rescue the cells from anoikis. These results support the hypothesis that PI3K/Akt activation and inhibition of anoikis depend on the combination of tyrosine kinase and small GTPase signals.
Discussion
Based on the preceding data, we suggest a regulatory mechanism to explain how cytoplasmic tyrosine kinases and small GTPases regulate PtdIns-3,4,5-P 3 production by type IA PI3K. This model also explains how the carboxy-terminally truncated neutralization of its inhibitory function by tyrosine phosphorylawere cultured on 0.9% agarose in MCDB base medium. EGF was used at tion allows small GTPases to activate PI3K through the GRD. The inhibitory domain and the GRD together form a molecular after 6 hr in suspension for immunoblot analysis. Cell viability was examined switch that regulates the enzyme.
after 10 days in suspension as described . C: A model of PI3K activation by tyrosine kinase signals and small GTPase signals. According to These data raise the question of the molecular mechanism this model, p85 binds, via its cSH2 motif, tyrosine-phosphorylated proteins through which tyrosine kinases and small GTPases regulate the and undergoes phosphorylation at Y688. Phosphorylation at this site funcswitch. The inhibitory domain, which consists of the cSH2 and tionally inactivates the p85 inhibitory domain. Neutralization of the inhibitory the adjacent LED motifs, was inactivated by a mutation (R649L) domain renders p85 responsive to PI3K activation signals that are transduced by small GTPases.
in the FLVR region of cSH2. Since this mutation eliminates binding to phosphotyrosine, we conclude that the inhibitory function of this domain depends on its binding to tyrosinephosphorylated molecules. One potential explanation for this data because the cSH2 domain alone, which should also bind result is that the overexpressed p85 inhibitory domain competes these sites, has no inhibitory activity. Therefore, the LED motif with endogenous p85 for binding to tyrosine-phosphorylated is an indispensable part of the inhibitory domain. The role of the LED motif is not clear to date. One potential molecules. However, this hypothesis cannot fully explain our clue regarding its function is that the inhibitory domain is modu-
The mechanism of PI3K activation via the synergistic action of two different classes of signaling molecules defines a signallar and functions in trans, despite the fact that it does not bind p110. This suggests that the LED motif may regulate the conforing paradigm for PtdIns-3,4,5-P 3 regulation. According to this paradigm, a given molecule may be the target of two simultanemation of p85, perhaps through electrostatic and/or hydrophobic interactions with the IKR motif. Changes in the conformation ously activated, converging pathways, one of which molecularly modifies the target so that it can be recognized by the other. of p85 may affect the activity of p110. One possible mechanism by which conformational changes of p85 regulate the activity Synergism between a variety of tyrosine kinases and small GTPases suggests that external signals may use different comof the catalytic subunit is that such changes may directly affect the conformation of the p85 bound p110. Alternatively, conforbinations of these two classes of molecules to activate PI3K. In agreement with this, a kinase-inactive mutant of Src (Figure mational changes of p85 may affect the ability of p110 to dimerize. This hypothesis is supported by earlier findings showing 8A) and a dominant-negative mutant of CDC42 (Clark et al., 1998) inhibit PI3K activation by integrin stimulation, and a domithat PI3K dimerizes in vitro and that dimerization is promoted by binding to tyrosine-phosphorylated peptides (Layton et al., nant-negative mutant of H-Ras partially inhibits PI3K activation by PDGF and NGF (Franke et al., 1995; Klinghoffer et al., 1996; . The interaction between the IKR and LED motifs was suggested by the abundance of conserved hydrophobic and Rodriguez-Viciana et al., 1994) . Moreover, in hematopoietic cells, PtdIns-3,4,5-P 3 induction by the IgE receptor, Fc⑀RI, or positively charged amino acids in the IKR motif and hydrophobic and negatively charged amino acids in the LED motif. Supportby the T cell receptor requires Rac1 signals (Djouder et al., 2001; Genot et al., 2000) . Data presented in this report showed ing the hypothesis that such interactions indeed take place and that they are functionally important are recent findings showing that the p85 inhibitory domain blocks Ras-induced transformation of NIH3T3 cells. In addition, they showed that both constituthat mutations designed to disrupt the interaction between the IKR and LED motifs abolish the function of the p85 inhibitory tively active Ras and EGF are required for Akt activation and protection from apoptosis. These results strongly support the domain (data not shown). The inhibitory function of the LED motif could be affected by conformational changes of p85 induced by physiological relevance of the model of PI3K activation described in this report. tyrosine phosphorylation. Cuevas et al. (2001) , indeed, proposed that phosphorylation of Y688 promotes intramolecular In summary, data in this report show that p85 contains a molecular switch that regulates PI3K in response to signals interactions between nSH2 and cSH2. Such interactions may induce conformational changes that affect the inhibitory activity transduced by tyrosine kinases and small GTPases. Given the significance of the PI3K pathway in oncogenesis, this molecular of the LED motif.
The preceding data suggest a model according to which PI3K switch defines an important target for future chemotherapeutic drugs. is inactive in quiescent cells, in part because the p85 inhibitory domains binds tyrosine-phosphorylated molecules with inhibitory
Experimental procedures
properties. Following signals that activate tyrosine kinases, p85 undergoes phosphorylation in a number of sites, including tyroCell culture, transfection, and plasmids sine 668. Since a Y668F mutation did not affect the function of NIH3T3 fibroblasts were cultured in Dulbecco's Modified Eagle's Essential the inhibitory domain while a phosphomimetic Y668D mutation Medium (DMEM) supplemented with 10% calf serum and antibiotics. Immorcompletely abolished its activity, we conclude that phosphorylatalized, nontumorigenic human keratinocytes (HaCaT cells) (Boukamp et al., 1988) and their tumorigenic variant expressing the activated H-Ras G12V tion of this site is sufficient to neutralize this domain. Neutraliza- (Boukamp et al., 1990) were obtained from N. Fusenig. Cells were transfected tion of p85 by phosphorylation may be mediated by one of using LipofectAMINE (GIBCO-BRL) or Fugene-6 (Roche) according to the several tyrosine kinases, including Src, Lck, Abl, EGF-R, manufacturer's protocols. All constructs, except where noted, were gener-PDGF-R, and IGF-R, which are known to phosphorylate this ated in the mammalian expression vector, CMV5. The Src myristoylation molecule (von Willebrand et al., 1998; Wymann and Pirola, 1998) signal (MGSSKSKPK), an extended Hemagglutinin epitope (HA) (MASSY- and to cooperate with small GTPases in PI3K activation (see PYDVPDYASLGGPSRST) , and a FLAG-epitope tag (MDYKDDDDK) were fused at the amino terminus of the indicated constructs. Green fluorescence Supplemental Figure S5 at http://www.cancercell.org/cgi/ protein (GFP) in pFred143(KH1035) was a gift from G. Pavlakis, p110-␣-content/full/1/2/181/DC1). This raises the question of the mech-CAAX in pMT2 was a gift from K. Kotani, and p110-␥-CAAX in pCDNA3 was anism through which phosphorylation of tyrosine 668 neutrala gift from M. Wymann. Additional details are available in the Supplemental izes the inhibitory domain. One possibility is that phosphorylaData at http://www.cancercell.org/cgi/content/full/1/2/181/DC1. tion alters the conformation of the protein and makes the GRD domain accessible to small GTPase signals. This conformational
In vivo labeling of PtdIns-3,4,5-P 3 PtdIns-3,4,5-P 3 was measured in lipid extracts of 32 P-labeled NIH3T3 cells change may be the direct outcome of phosphorylation. Alternaby thin-layer chromatography (Maehama and Dixon, 1998) . Approximately tively, phosphorylation of tyrosine 668 may selectively alter the 2 ϫ 10 5 NIH3T3 cells plated into 35 mm Petri dishes were transfected with spectrum of proteins that bind the cSH2 motif. Previous studies constitutively active H-Ras G12V, p85-WT, and p85⌬onc constructs in CMV5
by von Willebrand et al. (1998) indeed showed that phosphorylausing Fugene 6 (Roche). Sixteen hours later, the transfected cells were tion at this site in pervanadate-treated Jurkat cells selectively serum-starved for 5 hr and following this, they were labeled for 1.5 hr with alters the spectrum of p85 binding proteins. Please note that 100 uci/ml 32 P-orthophosphate in a phosphate-free buffer (10 mM Hepes selective shifts in the spectrum of proteins binding the PI3K [pH 7 .5], 136 mM NaCl, 4.9 mM KCl, and 5.5 mM glucose). ( Layton et al., 1998) . The conformational change that neutralizes the inhibitory domains may therefore be caused by the dissocia-
Akt kinase assay
tion of inhibitory molecules from the PI3K complex and/or by Akt/PKB kinase activation was determined either by measuring the phosphorylation of Akt at Thr308 using an antibody from Cell Signaling Technolthe association of the complex with activating molecules.
